The present invention relates to a composition, for preventing, remedying or treating female climacteric syndrome, containing loganin, a derivative of same or pharmaceutically acceptable salts of same as an active ingredient. Loganin, according to the present invention, enables an increase in the estradiol (17β-estradiol, E2) concentration in the blood of a menopausal mouse model and has shown effects such as: an increase in the estrogen receptor alpha expression in the uterus； remedying of uterine contraction and degeneration； a decrease in the size and accumulation of adipocytes in the abdominal adipose tissues and the liver； and weight loss. Therefore, loganin enables remedying of symptoms in menopausal women such as loss of estrogen, weight gain, and size increase in adipocytes and fat accumulation in the abdominal adipose tissues and the liver. Therefore, loganin and a composition comprising same as an active ingredient, according to the present invention, are expected to be utilized as a pharmaceutical preparation for preventing and remedying climacteric symptoms.
